Sclerotherapy with 3% polidocanol foam to treat second‐degree haemorrhoidal disease: Three‐year follow‐up of a multicentre, single arm, IDEAL phase 2b trial
Colorectal Disease2022Vol. 25(3), pp. 386–395
Citations Over TimeTop 10% of 2022 papers
Gaetano Gallo, Arcangelo Picciariello, Renato Pietroletti, Eugenio Novelli, Alessandro Sturiale, Roberta Tutino, Rita Laforgia, Elisabetta Moggia, Mauro Pozzo, Maurizio Roveroni, Vincenzo Bianco, Alberto Realis Luc, Antonio Giuliani, Elia Diaco, Gabriele Naldini, Mario Trompetto, Roberto Perinotti, Vito D’Andrea, Pierluigi Lobascio
Abstract
Sclerotherapy with 3% polidocanol foam is gradually establishing itself in the treatment of bleeding HD due to its repeatability, safety, convenience in terms of direct and indirect costs with the absence of discomfort for the patient as well as AEs rather than an excellent overall success rate.
Related Papers
- → Sclerotherapy in venous malformation(2013)67 cited
- → Comparative Study of Duplex-Guided Foam Sclerotherapy and Duplex-Guided Liquid Sclerotherapy for the Treatment of Superficial Venous Insufficiency(2004)57 cited
- → Sclerotherapy: a study comparing polidocanol in foam and liquid form(2010)50 cited
- Efficacy and Safety of Sclerotherapy with Polidocanol Foam for Superficial Venous Malformation(2014)
- → The Efficacy of Polidocanol foam Sclerotherapy in Treatment of Infantile Hemangioma and Slow-Flow Vascular Malformation(2016)1 cited